Day One Biopharmaceuticals (DAWN) Q4 2025: Ojemda Revenue Jumps 172% as Persistence and Pipeline Reshape Growth Trajectory

2026-02-24 | By EarningsIQ Research

Day One Biopharmaceuticals delivered a breakout year with Ojemda’s rapid adoption and strong revenue growth, underpinned by robust patient persistence and expanding clinical evidence. Management’s disciplined financial execution, pipeline momentum, and a major acquisition set up a multi-year growth story, but the next leg will hinge on solidifying Ojemda as the second-line standard and advancing new assets toward registration. Investors should watch for persistence levers, frontline trial enrollment, and the mid-year readout of the Emily program as critical inflection points for 2026.

Summary

• Persistence-Driven Commercial Model: Ojemda’s long treatment durations and high payer approval are fueling durable revenue growth.
• Pipeline Acceleration: Integration of the Emily antibody drug conjugate and advancing DAY 301 signal a broadening growth platform beyond PLGG.
• 2026 Inflection Watch: Key catalysts include Firefly 2 trial enrollment, global expansion, and mid-year Emily data for ACC registration.

Performance Analysis

Day One Biopharmaceuticals closed its first full commercial year with Ojemda, a targeted therapy for pediatric low-grade glioma (PLGG), driving the business to triple-digit revenue growth and a strong foundation for 2026. The company reported $155.4 million in net product revenue for 2025, reflecting a 172% year-over-year increase, and more than 4,600 total prescriptions, up over 180% from the prior year. Fourth quarter net product revenue reached $52.8 million, representing 37% sequential growth, with prescription volumes exceeding 1,300 even amid typical holiday seasonality.

This growth was enabled by high physician adoption, strong payer coverage (over 95% approval rates), and a median duration of therapy trending toward 19 months, indicating robust patient persistence. Management highlighted that Ojemda’s revenue now exceeds combined cost of sales and SG&A, demonstrating operating leverage and scalability. Gross-to-net remained stable within the 12% to 15% range. Operating expenses declined year-over-year due to the absence of prior one-time licensing costs, and the company ended the year with $441 million in net cash and no debt, providing significant financial flexibility for continued pipeline investment.

• Persistence as Revenue Engine: Median therapy durations near 19 months, with stacking effect from long treatments driving sequential growth.
• Payer Landscape Advantage: Over 95% coverage and minimal reliance on free drug programs enable rapid patient onboarding and revenue recognition.
• Operating Model Leverage: Revenue now outpaces core operating costs, supporting future investment without diluting financial discipline.

Day One’s financials now reflect a company transitioning from launch to sustainable growth, with Ojemda’s performance providing a template for future pipeline commercialization.

Executive Commentary

Strategic Positioning

1. Ojemda’s Commercial Foundation in PLGG

Ojemda, a targeted therapy for pediatric low-grade glioma, is now the clear commercial backbone for Day One. The company’s focus on the second-line setting has yielded high physician confidence, rapid adoption, and payer support. Management’s priority is to solidify Ojemda as the standard of care in second-line PLGG, leveraging three-year Firefly 1 trial data showing durable responses and extended time-to-next treatment. The next milestone is completing enrollment for the frontline Firefly 2 trial, opening a path to expand Ojemda’s label and market opportunity.

2. Persistence and Patient Management as Key Growth Levers

Patient persistence is emerging as a central commercial lever. Day One’s analysis identified four groups with higher persistency: earlier-line patients, experienced prescribers, dose-adjusted patients, and those enrolled in patient support programs. The company is now targeting education and support initiatives to further extend treatment durations, which directly drive revenue and support long-term growth projections.

3. Pipeline Diversification and M&A Integration

The acquisition of Mursana and integration of the Emily (MLE) antibody drug conjugate program marks a strategic pivot toward pipeline diversification. Emily’s Phase I data in adenoid cystic carcinoma (ACC) show antitumor activity and a manageable safety profile, with a mid-2026 data update and regulatory discussions planned. Day One is also progressing DAY 301, another antibody drug conjugate targeting PTK7, with early signals of efficacy in dose escalation. These programs are positioned to extend Day One’s reach into additional rare oncology indications, supporting a multi-asset growth model.

4. Financial Discipline and Capital Allocation

Day One’s financial management remains conservative, with no debt and a large cash reserve. The company’s ability to fund operations and pipeline expansion without near-term financing reduces dilution risk and supports flexibility for further business development. Management reiterated a disciplined approach, seeking assets with high unmet need, strong early data, and scalable commercialization potential.

5. Global Expansion and Regulatory Strategy

Ex-U.S. growth is on the horizon, with partner Ipsen preparing for regulatory submissions in Europe and other territories. This strategy leverages partnerships for broader market access while Day One retains focus on U.S. execution and pipeline advancement.

Key Considerations

Day One’s 2025 performance signals a pivotal transition from single-product launch to a diversified, persistence-driven oncology platform. The company’s ability to maximize Ojemda’s commercial life, execute on pipeline milestones, and maintain financial rigor will shape its long-term value creation.

Key Considerations:

• Persistence Optimization: Initiatives to improve patient duration on therapy—through physician education, support programs, and dose adjustment—are a direct lever for revenue expansion.
• Pipeline Catalysts: Mid-year Emily data in ACC and DAY 301 updates will test Day One’s ability to replicate Ojemda’s commercial model in new indications.
• Regulatory Readouts: Firefly 2 trial enrollment and subsequent data will determine Ojemda’s path to frontline standard-of-care status, a major TAM expansion event.
• Global Market Access: Ipsen’s ex-U.S. efforts could unlock new revenue streams, though execution risk remains as approvals and launches progress.
• Financial Flexibility: Large cash reserves and no debt provide insulation against market volatility and support opportunistic business development.

Risks

Key risks include Ojemda’s reliance on a single indication for the bulk of current revenue, potential delays or negative outcomes in pivotal pipeline trials (especially Firefly 2 and Emily in ACC), and competitive threats from new entrants or evolving standards of care in pediatric and rare oncology. Execution on persistence initiatives and successful integration of new assets remain critical to sustaining growth. Regulatory and reimbursement changes, as well as unforeseen safety concerns, could also impact the commercial trajectory.

Forward Outlook

For Q1 2026, Day One guided to:

• Continued strong demand for Ojemda, with sequential growth expected to persist into the new year.
• Gross-to-net in the range of 16% to 19% as payer dynamics remain favorable.

For full-year 2026, management maintained guidance:

• Ojemda net product revenue of $225 million to $250 million, implying over 50% year-over-year growth at the midpoint.

Management highlighted several factors that will drive 2026 performance:

• Persistence optimization and new patient starts as central growth levers.
• Upcoming data readouts and regulatory milestones for pipeline programs.

Takeaways

Day One’s 2025 performance validates its persistence-focused commercial model and sets the stage for a year of pipeline-driven catalysts. The company’s ability to translate clinical evidence into durable revenue, expand into new indications, and maintain financial discipline will be decisive in 2026 and beyond.

• Persistence Drives Growth: Long therapy durations and payer coverage underpin Ojemda’s expanding revenue base, with further gains possible through targeted initiatives.
• Pipeline Execution Is Next Test: Emily and DAY 301 represent near-term diversification opportunities, but require successful data and regulatory navigation.
• Frontline Expansion and Global Reach: Firefly 2 trial progress and ex-U.S. launches could transform Ojemda’s addressable market if execution remains strong.

Conclusion

Day One Biopharmaceuticals enters 2026 with momentum, a proven commercial engine in Ojemda, and a pipeline poised for value-creating readouts. The company’s next phase hinges on persistence optimization, pipeline advancement, and disciplined capital allocation to sustain multi-year growth in rare oncology.

Industry Read-Through

Day One’s experience highlights the power of persistence-driven revenue models in rare disease oncology, where long therapy durations and high payer approval can quickly transform financial profiles post-launch. The focus on time-to-next treatment and real-world patient management is increasingly relevant as new targeted therapies seek to differentiate on durability and quality of life, not just response rate. Pipeline diversification via antibody drug conjugates and disciplined M&A is becoming a playbook for rare oncology companies seeking to move beyond single-product risk. The importance of payer dynamics, patient support programs, and global partnerships will resonate across the biotech sector as competition intensifies and investors demand capital-efficient growth strategies.

DAWN Healthcare Biotechnology Oncology Persistence Pipeline Rare Disease Commercialization